Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

Teva Rejected by U.S. Supreme Court on Generic Copaxone Delay
2014-04-18 20:10:12.668 GMT


By Greg Stohr
April 18 (Bloomberg) -- A U.S. Supreme Court justice
rejected Teva Pharmaceutical Industries Ltd.’s bid to block
generic versions of its Copaxone multiple-sclerosis drug while
the court hears the company’s appeal in a patent clash.
The rebuff by Chief Justice John Roberts means Teva may
face generic competition as soon as next month. Mylan Inc.,
Momenta Pharmaceuticals Inc. and Novartis AG’s Sandoz are
positioned to start selling generic Copaxone in late May,
although they would risk having to pay damages if Teva
ultimately wins the patent case. Momenta and Sandoz are working
together.
Teva now has the option of asking another justice to
intervene. A delay would give Teva more time to switch patients
from the 20-milligram dose that is the subject of the legal
fight to a 40-milligram version that the company says is covered
by other patents.